Human Vascular Smooth Muscle Cells Express Receptors for CC Chemokines

From Rhône Poulenc–Rorer, Dagenham Research Centre, Discovery Biology, Essex (I.M.H., S.T., J.R.P., A.G.R., R.J.W.); the University of Bath, Department of Pharmacology, (N.J.J., G.S., J.W.); and Gloucestershire Royal Hospital (J.J.E.), UK.

Correspondence to Dr Ian Hayes, Discovery Biology, Rhône Poulenc–Rorer, Dagenham Research Centre, Rainham Road South, Dagenham, Essex, RM10 7XS, UK.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Arteriosclerotic lesions are characterized by the accumulation of T lymphocytes and monocytes and the proliferation of intimal smooth muscle cells. Expression of the chemokine monocyte chemoattractant protein-1 (MCP-1) has been observed in arteriosclerotic plaques and has been proposed to mediate the transendothelial migration of mononuclear cells. More recently, MCP-1 has been proposed to affect the proliferation and migration of vascular smooth muscle cells (VSMCs). We have used reverse transcription–polymerase chain reaction (RT-PCR) to investigate chemokine mRNA expression in human arteriosclerotic lesions obtained from surgical biopsy of diseased vascular tissue and show, in addition to MCP-1, expression of the chemokine macrophage inflammatory protein-1 (MIP-1) at higher levels than in "normal" aortic tissue. We have also used RT-PCR to characterize the expression of known chemokine receptors by primary human VSMCs. Messenger RNA for the MIP-1/RANTES receptor, CCR-1, and the MCP-1/MCP-3 receptor, CCR-2, was expressed by unstimulated VSMCs grown under serum-free culture conditions for 24 hours. The receptors CCR-3, CCR-4, CCR-5, CXCR-1, and CXCR-2 were not expressed by VSMCs. The presence of functionally coupled receptors for MIP-1 on VSMCs was demonstrated by specific binding of biotinylated MIP-1 and increases in intracellular Ca²⁺ levels after exposure to this chemokine. Taken together, these results suggest that chemokines are likely to be involved in arteriosclerosis and may play a role in modulating the function of VSMCs in vivo.

Key Words: chemokines • receptors • humans • vascular smooth muscle cells • arteriosclerosis

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
T lymphocytes, macrophages, and associated cytokines are well accepted as orchestrators of many chronic inflammatory diseases, including asthma/allergy, arthritis, and multiple sclerosis. There is now accumulating evidence for the involvement of humoral and cellular immune reactions in the development of arteriosclerosis.^{1 2 3} Growth factors and cytokines derived from inflammatory cells can stimulate migration and proliferation of VSMCs and the formation of mature lesions.⁴

Chemokines are now widely accepted as playing a pivotal role in the recruitment of leukocytes from the blood compartment into tissues, and their presence in human inflammatory disease has been widely documented.^{5 6 7} The chemokine superfamily can be sorted into four groups on the basis of the structural arrangement of four conserved cysteine residues. In the CXC family, the first two cysteines are separated by an intervening amino acid; these chemokines, which include IL-8, are generally involved in neutrophil and T-cell chemotaxis and activation. The CC chemokines, such as MCP-1, MIP-1, and RANTES (regulated on activation, normal T cell expressed and secreted), have two adjacent cysteine residues and act more generally on monocyte/macrophages, lymphocytes, eosinophils, and basophils.^{8 9 10} The C and CX₃C groups each have only one known member, both of which act on T cells.^{11 12} The biological responses to chemokines are mediated by a family of seven-transmembrane G-protein–coupled receptors.¹³ At least eight human CC chemokine receptors have been cloned (CCR-1 through CCR-8)^{14 15 16 17 18 19 20 21 22 23 24} and four receptors for the CXC chemokines (CXCR1 through CXCR4).^{25 26 27 28 29} The majority of these receptors have considerable overlapping ligand specificity and to date have generally been found on leukocytes.

The chemokine MCP-1 may play an important role in the establishment and propagation of arteriosclerosis, since mRNA and protein have been detected in arteriosclerotic plaques.^{30 31 32} In addition to being secreted by stimulated human macrophages,³³ MCP-1 is also produced by cultured VSMCs and endothelial cells stimulated with cytokines^{34 35 36} and minimally modified low density lipoprotein.^{37 38 39} RANTES and MIP-1 expression has also been documented in a range of chronic inflammatory diseases.^{5 40} We and others^{36 41} have recently demonstrated that RANTES is expressed by stimulated human VSMCs and endothelial cells.

The ability of vascular smooth muscle to respond to proinflammatory cytokines shows that it has characteristics of an immune-regulated tissue. There is also some recent evidence that VSMCs can respond to certain chemokines, including IL-8, MCP-1, and TCA3.^{42 43 44 45} The purpose of this study was to determine whether other chemokines, in addition to MCP-1, are expressed in arteriosclerosis and also whether isolated human VSMCs express receptors that enable them to respond to these chemokines. Here we report the expression of MIP-1 and RANTES, as well as MCP-1, mRNA in arteriosclerotic lesions. We also report that human VSMCs express mRNA for the MIP-1/RANTES receptor CCR-1 and the MCP-1/MCP-3 receptor CCR-2. Binding and functional studies are described that demonstrate the presence of functionally coupled receptors for MIP-1 on VSMCs, CCR-1 being a candidate receptor.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Reagents
Cytokines and chemokines were obtained from Peprotec. All cell culture reagents and HI-FBS were purchased from GIBCO-BRL. Oligonucleotide primers were synthesized by Cruachem and GIBCO-BRL. Standard reagents were from Sigma or Fisons.

Isolation of Peripheral Blood Leukocytes
Whole blood was obtained from normal donors, and standard methods were used to prepare PBMCs, CD 16⁺ neutrophils, and an eosinophil/basophil fraction. In brief, blood was citrated and centrifuged (10 minutes at 1500g) to remove plasma. PBMCs were separated from red blood cells and neutrophils after density-gradient centrifugation on Lymphoprep (Nycomed). Red blood cells were removed from neutrophils by centrifugation through dextran T500. Eosinophils and basophils were separated from CD 16⁺ cells by negative selection, using magnetic beads coupled to anti–CD 16 antibodies (MACS, Miltenyi Biotec) as described by Hansel et al.⁴⁶

Isolation and Culture of SMCs
SMCs were isolated from human saphenous vein by a standard explant method.⁴⁷ Briefly, small moistened pieces of tissue (6 mm²) were placed intima side down in a tissue-culture flask and left to adhere for 2 hours, and then the base of the flask was carefully flooded with culture medium consisting of Dulbecco's modified Eagle's medium containing 15% HI-FBS, penicillin (10 U/mL), streptomycin (10 µg/mL), and fungizone (0.5 µg/mL) and left undisturbed for 2 to 3 weeks. Primary isolates were grown to confluence in culture medium and passaged using trypsin/EDTA. Cells were fixed for 10 minutes in ice-cold methanol and immunocytochemical analysis showed them to be positive for the smooth muscle cell–specific marker -actin. Cells were used from five different patients between passages 2 and 9. To render cells quiescent, FBS was removed from the culture medium for 24 hours before all experiments. For RT-PCR studies, cells were treated for 3 to 4 hours with serum-free culture medium alone as unstimulated controls or with culture medium containing 15% HI-FBS or TNF (30 ng/mL) before isolation of RNA. Treatments were applied to cells from the same donor.

Biotinylated MCP-1 and MIP-1 Binding Studies
Binding of MCP-1 and MIP-1 to VSMCs was measured using Fluorokine kits (R & D Systems) according to the manufacturer's instructions. Briefly, VSMCs were grown to confluence in tissue-culture flasks coated with 1% gelatin and then depleted of serum for 24 hours. Cells were harvested with trypsin/EDTA, washed three times, and resuspended in PBS. We have previously found that trypsin treatment of MCP-1 receptor-transfected HEK 293 cells does not affect their ability to bind or respond to MCP-1.⁴⁸ Biotinylated MIP-1, MCP-1 (at final concentration of 150 nmol/L), or negative control protein (biotinylated soybean trypsin inhibitor) was incubated at 4°C with 1x10⁵ cells, and binding was detected by using avidin-FITC. Cells were washed and analyzed by flow cytometry on a FACS Vantage cell sorter (Becton Dickinson), using excitation at 488 nm and fluorescence emission of 520 nm. The specificity of MIP-1 binding was tested either by preincubating the biotinylated MIP-1 with anti-human MIP-1 antibody for 15 minutes at room temperature or by the addition of 100-fold excess of nonbiotinylated MIP-1.

Measurement of Intracellular Ca²⁺ Elevation
VSMCs were seeded onto sterile glass coverslips coated with 0.1% type 1 collagen. The cells were allowed to adhere at 37°C overnight in serum-free medium. Washed cells were loaded with fura 2-AM (Molecular Probes) mixed with an equal volume of 25% pluronic F-127 (Molecular Probes) diluted to 5 µmol/L in HBSS containing BSA (1 mg/mL) and Ca²⁺/Mg²⁺(1 mmol/L) at 37°C for 30 minutes. Cells were washed and left to equilibrate in HBSS for 30 minutes before use. The calcium flux was measured using a PTI dual wavelength spectrofluorimeter (Photon Technology International) with excitation at 340 and 380 nm and emission at 510 nm using a fiber-optic light guide to illuminate a microscope stage. Elevation in Ca²⁺ was assessed as an increase in the ratio of the signals at the two excitation wavelengths. Coverslips were placed in a heating chamber at 37°C and bathed in 500 µL HBSS. Groups of approximately five cells were selected, and the Ca²⁺ flux in response to 500 nmol/L chemokine was measured. Thrombin (4 U/mL) was used as a positive control to confirm cell viability.

RNA Isolation
Total cellular RNA was extracted from VSMCs, PBMCs, neutrophils, eosinophil/basophils, and tissues, using a commercial solution containing guanidinium thiocyanate (RNAsol, Tel-Test) as described by the manufacturer. Human surgical biopsy specimens (50 to 200 mg) from abdominal aortic aneurysm and carotid endarterectomy (Gloucestershire Royal Hospital) and control tissue from organ transplant donors (Harefield Hospital) were snap-frozen and stored in liquid N₂ immediately after surgical isolation. These were added to a solution of RNAsol while still frozen and were homogenized using an UltraTurax (Esslab). The homogenate was cleared by centrifugation (10 minutes at 3500g) and RNA extracted as described by the manufacturer. Poly (A⁺) messenger RNA was purified from total cellular RNA by using a QuickPrep Micro purification kit (Pharmacia), as described by the manufacturer.

RT-PCR
Poly (A⁺) RNA (20 to 200 ng) was heated for 10 minutes at 65°C, cooled to room temperature, and reverse transcribed in a 20-µL reaction containing 1x Molony murine leukemia virus reverse transcriptase buffer (Promega, ), 5 µmol/L oligo (dT)_12–18 (Pharmacia), 1 mmol/L dNTPs, 2 µg acetylated BSA, 40 U RNasin (Promega), and 200 U Molony murine leukemia virus reverse transcriptase (Promega) at 37°C for 1 hour. Reactions were made up to 60 µL with sterile distilled water and stored at -20°C. Equal aliquots of cDNA (5 µL) were PCR amplified in a 100-µL reaction, containing 1x PCR buffer II and 1.5 mmol/L MgCl₂ (Applied Biosystems), 0.2 mmol/L dNTPs, 0.4 µmol/L sense and antisense primers, and 2.5 U AmpliTaq DNA polymerase. The oligonucleotide sequence, annealing temperature, and product size for each gene-specific primer pair used are shown in the Table. The conditions for amplification were 5 minutes at 94°C, 35 cycles of 1 minute at 94°C, 1 minute at 55°C to 58°C, 2 minutes at 72°C, followed by an extension for 10 minutes at 72°C. PCR products were resolved by electrophoresis on 2% agarose gels and visualized by ethidium bromide staining. Images were captured by video camera and GRABBIT software (UV Products).

Gene-specific oligonucleotide primers were designed using Lasergene software (DNASTAR). To control for genomic DNA contamination in PCR reactions, sense and antisense primers were designed to span an intron-exon splice site. Chemokine receptor genes, however, do not contain intron sequences. As a consequence, an identical parallel PCR reaction was performed, in which reverse transcriptase was omitted from the reverse transcription reaction.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Chemokines MIP-1, RANTES, and MCP-1 Are Expressed in Arteriosclerosis
To determine whether other chemokines, in addition to MCP-1, are expressed in arteriosclerosis, we have examined biopsy specimens of aortic, iliac, and carotid arteries, which were isolated during surgical procedures for vascular disease (abdominal aortic aneurysm and carotid endarterectomy). Each specimen was assessed histopathologically and shown to exhibit extensive arteriosclerotic lesions. Messenger RNA expression was measured by RT-PCR for MIP-1, MCP-1, MCP-3, and RANTES, relative to the loading control gene GAPDH. As shown in Fig 1, mRNA for MIP-1, MCP-1, and RANTES was readily detected in all specimens of diseased tissue, as was GAPDH mRNA; MCP-3 mRNA expression could not be detected. The normal tissue used as a control (thoracic aorta obtained from organ transplant donors) did not express MCP-3 or MIP-1. Some of the specimens showed low expression of MCP-1, and RANTES was detected in all normal tissues examined. No obvious arteriosclerotic lesions were detected in control specimens.

View larger version (51K): [in this window] [in a new window]   Figure 1. Chemokine mRNA expression in arteriosclerosis. Poly (A+) RNA was extracted from arterial tissue, isolated during surgical procedures for vascular disease (abdominal aortic aneurysm: lanes 1 and 2, aortic wall from a 77-year-old male; lanes 3 and 4, aortic wall from a 75-year-old female; lanes 5, 6, and 7, iliac artery from a 75-year-old female, and carotid endarterectomy; lanes 8 and 9, carotid artery from a 71-year-old female). Each tissue sample exhibited extensive arteriosclerotic disease pathology. Control tissue was obtained from organ transplant donors (thoracic aorta: lanes 10, 11, 12, 13, and 14, from 40-, 28-, 23-, and 39-year-old females, and 27-year-old male, respectively). Gene expression was measured by RT-PCR for MCP-1, MCP-3, MIP-1, and RANTES, relative to the loading control GAPDH.

Chemokine Receptor mRNA for CCR-1 and CCR-2 Are Expressed by Human VSMCs
With the use of RT-PCR and by designing gene-specific primers, we were able to distinguish between closely related members of the chemokine receptor family, which share 20% to 80% sequence identity.¹³ Gene-specific primer pairs were validated by examining their expression in PBMC, neutrophil, and eosinophil/basophil cell fractions of human peripheral blood (Fig 2). CCR-1, -2, -4, and -5 mRNA was significantly expressed by PBMCs. CCR-3 was predominantly expressed by the eosinophil/basophil fraction, while both CXCR-1 and CXCR-2 were expressed by neutrophils. The authenticity of each RT-PCR product was confirmed by DNA sequencing.

View larger version (27K): [in this window] [in a new window]   Figure 2. Differential expression of chemokine receptor mRNA. Poly (A+) RNA was isolated from human PBMCs (P), neutrophils (N), eosinophils (E), and VSMCs isolated from three individuals (a, b, and c). VSMCs were cultured for 24 hours in the absence of serum and then treated for 3 to 4 hours with serum-free medium alone as a control (1) or medium containing 15% FBS (2) or 30 ng/mL TNF (3). Gene expression was measured by RT-PCR for CCR-1, CCR-2, CCR-3, CCR-4, CCR-5, CXCR-1, and CXCR-2, relative to the loading control GAPDH. To control for the presence of genomic DNA, control cDNA reactions in which reverse transcriptase was omitted were prepared in parallel; these were uniformly negative (data not shown).

To determine whether chemokine receptors are expressed by VSMCs, human VSMCs were isolated from saphenous vein and cultured by explant. The results of representative experiments from three individual patients (a, b, and c) are shown in Fig 2. Both CCR-1 and CCR-2 mRNA was significantly expressed by unstimulated VSMCs (cultured for 24 hours in the absence of serum: lane 1, patients a, b, and c), at levels comparable to those found in peripheral blood cells under identical PCR conditions. None of the other chemokine receptor mRNAs tested were detected.

We have examined whether chemokine receptor mRNA was differentially regulated by mitogenic stimuli or proinflammatory cytokines. VSMCs were treated for 3 to 4 hours with media containing either 15% HI-FBS or 30 ng/mL TNF. This concentration of TNF induces chemokine expression in VSMCs.³⁶ The results were inconclusive; in one culture stimulation with FBS appeared to downregulate the expression of both CCR-1 and CCR-2 mRNA (Fig 2, patient a; compare lanes 1 and 2); however, this result was not found in the other two cultures examined (patients b and c). Stimulation with TNF did not appear to regulate receptor mRNA expression. None of the other chemokine receptor mRNAs tested were detected after stimulation with either FBS or TNF.

MIP-1 Binds to Human VSMCs
The ligands known to bind to CCR-1 are MIP-1, RANTES, MCP-3, and to a lesser extent MCP-1.^{14 20 49} The known ligands for CCR-2 are MCP-1 and MCP-3.^{15 49} Human VSMCs were incubated with biotinylated MIP-1 or MCP-1 to determine whether receptors for these ligands were expressed on the cell surface. Bound ligand was measured by flow cytometry. MIP-1 was found to bind to VSMCs, shown as a rightward shift in the fluorescence peak compared with the negative control (Fig 3). Binding was completely blocked by preincubation of the biotinylated MIP-1 with anti–MIP-1 neutralizing antibodies or by competition with 100-fold excess of nonbiotinylated MIP-1 (n=5). No binding was detected for MCP-1 (data not shown).

View larger version (20K): [in this window] [in a new window]   Figure 3. Flow cytometric analysis of MIP-1–biotin binding to human VSMCs. Serum-starved VSMCs were trypsinized and resuspended in PBS (1x105 cells per assay). Cells were incubated at 4°C with MIP-1–biotin (150 nmol/L) or a biotinylated control protein, followed by avidin-FITC. Washed cells were analyzed by flow cytometry in which accumulated events were gated against the biotinylated negative control. Biotin–MIP-1 caused a shift to the right. Binding was displaced by preincubation with anti–MIP-1 antibody or coincubation with nonbiotinylated MIP-1 (1.5 µmol/L). The analysis included 20 mg/mL propidium iodide to enable the exclusion of nonviable cells. Results are representative of five separate experiments in which the mean fluorescence intensity for MIP-1 binding was 26±3.3 and 15±2.3 for antibody displacement.

Identification of a Functional MIP-1 Response in Human VSMCs
Chemokine-stimulated elevation of cytosolic Ca²⁺ concentration is a characteristic response of most leukocyte chemokine receptors. Transient Ca²⁺ elevation in adherent VSMCs could be reproducibly induced by 500 nmol/L MIP-1. The amplitude of the response was variable, but a typical example is shown in Fig 4a. A lower concentration of 100 nmol/L MIP-1 did not induce a response. Previous experience with inflammatory cells would suggest that the relatively prolonged Ca²⁺ elevation observed after exposure to MIP-1 is indicative of a sustained Ca²⁺ influx response. This finding contrasts with the transient response to thrombin, which appears to be mainly composed of Ca²⁺ mobilization followed by a brief Ca²⁺ influx. A smaller Ca²⁺ elevation occurred in response to 500 nmol/L MCP-1 (Fig 4b) but was not seen consistently in all cultures examined. Cells were viable, as shown by their ability to respond to thrombin. The chemokines IL-8 and RANTES, tested at both 100 and 500 nmol/L, did not cause Ca²⁺ elevation (data not shown).

View larger version (28K): [in this window] [in a new window]   Figure 4. Elevation in intracellular Ca2+ in adherent VSMCs caused by MIP-1 and MCP-1. Adherent smooth muscle cells were loaded with fura 2-AM, washed, and Ca2+ flux was measured by changes in ratio of the fluorescence signals at the excitation wavelengths of 340 and 380 nm using a spectrofluorimeter linked to a microscope. Cells were left to equilibrate at 37°C in HBSS (500 µL). They were then stimulated with 20 µL MIP-1 (a) or MCP-1 (b) to give a final concentration of 500 nmol/L. When Ca2+ had returned to basal levels, the cells were restimulated with 4 U/mL thrombin, which was used as a positive control. The example shown is of a representative experiment.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The monocyte chemoattractant protein MCP-1 was the first chemokine to be described in arteriosclerotic plaques.³⁰ It has been proposed that MCP-1 plays a key role in the recruitment of mononuclear cells into atherosclerotic lesions.⁵⁰ The presence of mRNA for MIP-1 and RANTES has previously been described in carotid plaque and coronary arteries obtained from transplanted hearts.^{40 51} We have shown in this study that in addition to MCP-1, the chemokines MIP-1 and RANTES are also expressed in spontaneously occurring arteriosclerosis from a number of sites, namely the abdominal aorta and the carotid and iliac arteries. RANTES mRNA was also expressed in all control samples (aorta); however, while apparently healthy, it is possible that these tissue specimens were affected by early arteriosclerotic events. These chemokines, in addition to being chemotactic for monocytes, are also potent chemoattractants and activators of T lymphocytes, which are present in arteriosclerotic lesions.^{1 2 3 40} The role of the T cell in arteriosclerosis is still unclear, but cytokines produced by these lymphocytes undoubtedly affect vascular-immune interactions.

Our studies with atherosclerotic tissue do not enable identification of the cell types producing chemokines. Chemokine production from inflammatory cells has been well documented, but we and others have also shown in in vitro studies that smooth muscle cells can be potent sources of chemokines, including IL-8, MCP-1, RANTES, and MIP-1, when stimulated with proinflammatory cytokines.^{36 52 53} These chemokines can also be produced by stimulated endothelial cells.^{34 37 41 54 55}

We have shown that cultured human VSMCs constitutively express mRNA for the chemokine receptors CCR-1 and CCR-2. The recognized ligands for CCR-1 are MIP-1, RANTES, MCP-3, and to a lesser extent MCP-1,^{14 20 49} while CCR-2 binds MCP-1 and MCP-3.^{15 49} Binding studies clearly show that our VSMCs express an MIP-1 binding protein on the cell surface. In addition to CCR-1, known MIP-1 binding proteins include CCR-4 and CCR-5.^{19 21 56} However, the absence of mRNA for these receptors implies that CCR-4 and CCR-5 is not the identity of the MIP-1 binding protein. Our data are therefore consistent with the possibility that CCR-1 mRNA is correctly processed and expressed on the VSMC surface; however, absolute identity must await detection at the protein level.

Chemokine-stimulated cytosolic Ca²⁺ elevation appears to be a consequence of signaling via phospholipase C–coupled G-protein receptors. MIP-1 consistently caused an elevation of intracellular Ca²⁺ in VSMCs. We were unable to detect a similar increase in response to another CCR-1 ligand, RANTES. The MIP-1 response was not detected at concentrations below 500 nmol/L, and since RANTES has a lower potency than MIP-1 for CCR-1, still higher concentrations of RANTES may have been needed to elicit a response.¹⁴ However, such higher concentrations were not tested because it was considered that the physiological relevance would be questionable. It is also possible that in VSMCs the RANTES response is not coupled to an elevation in intracellular Ca²⁺. We have previously observed that this is certainly the case for primary T lymphocytes, which exhibit chemotactic responses but fail to show Ca²⁺ elevation in response to RANTES.⁵⁷ It must also be considered that the MIP-1 receptor expressed was not CCR-1 but another as yet unidentified chemokine receptor. MCP-1 caused a much smaller Ca²⁺ flux, which was not seen consistently in all cells examined. Since both CCR-1 and CCR-2 can bind MCP-1, this functional response could be occurring via either receptor, although CCR-1 has a low affinity for MCP-1.¹⁴ The presence of a functional MCP-1 response seems to contradict the inability to detect MCP-1 binding to VSMCs when a fluorokine kit was used, which we have previously shown detects MCP-1 binding in receptor-transfected HEK cells.⁴⁴ The binding assay may be insufficiently sensitive to pick up binding if receptor density per cell is low. Others have reported problems detecting chemokine binding to cells that produce functional responses to the same chemokine.¹⁴

An increase in cytosolic Ca²⁺ and inositol lipid hydrolysis are signals often associated with cell proliferation and migration. These functional responses have previously been shown in VSMCs stimulated with IL-8, MCP-1, or TCA3. Yue et al⁴² showed that IL-8 was able to stimulate the growth of rat and human VSMCs and the migration of rat VSMCs, although it is unclear how these signals may be transmitted; Schonbeck et al⁵⁸ were unable to measure IL-8 binding to human VSMCs. This observation is in agreement with our inability to detect CXCR-1 or -2 receptor mRNA. MCP-1 also has functional effects on VSMCs, but these seem to vary depending on the species used. In rat VSMCs, MCP-1 appears to inhibit growth and mitogen-activated protein kinase activity.⁴³ Since we completed these studies, Xu et al⁵⁹ reported that porcine VSMCs have mRNA for the MCP-1 receptor CCR-2, and MCP-1 was reported to induce VSMC migration and proliferation. In addition, Luo et al⁴⁵ have demonstrated that the CC chemokine TCA3 but not MCP-1 or MIP-1 can induce proliferation of rat VSMCs, although all caused some migration. In our study on human VSMCs, we have demonstrated that MIP-1 and to a lesser extent MCP-1, but not IL-8 or RANTES, induce an elevation in cytosolic Ca²⁺, together with a clear demonstration of MIP-1 binding. The functional significance of this response is currently being investigated.

Our results suggest that CCR-1 and possibly CCR-2 are expressed constitutively on quiescent cultured human VSMCs and are not upregulated by proinflammatory cytokines. Preliminary results suggest that FBS may be able to downregulate chemokine receptor mRNA expression in VSMCs, although the functional significance remains to be investigated. It may be speculated that chemokines and their receptors play a role in homeostasis in the normal vessel and/or in response to injury. MCP-1 mRNA is rapidly upregulated 1 to 4 hours after injury to rabbit aorta, preceding the migration and proliferation of VSMCs.⁶⁰ Low levels of particular chemokines may prevent the normal VSMC layer from proliferating. MIP-1 is an unusual chemokine in this respect, since it has been shown to inhibit the proliferation of several cell types, including hematopoietic stem cells, dermal keratinocytes, and spermatogonia.^{61 62 63} It remains to be seen how MIP-1 affects VSMC function.

Although chemokines were initially identified for their ability to induce selective recruitment of leukocyte populations, they have now been shown to have a broad range of functions, including the modulation of HIV cellular uptake,^{64 65} keratinocyte proliferation,⁶² effects on the vasculature such as angiogenesis, and aspects of smooth muscle cell function such as chemotaxis and proliferation.⁶⁶ Further studies are clearly needed to determine whether chemokine receptors on VSMCs play a role in affecting the course of arteriosclerosis in vivo. Nevertheless, the VSMC must now be regarded as a truly immune-responsive cell able to both produce and respond to chemokines.

	Selected Abbreviations and Acronyms

 

HI-FBS = heat-inactivated fetal bovine serum IL = interleukin MCP = monocyte chemoattractant protein MIP = macrophage inflammatory protein PBMC = peripheral blood mononuclear cells RT-PCR = reverse transcription–polymerase chain reaction TNF = tumor necrosis factor VSMC = vascular smooth muscle cell

	Acknowledgments

 
This study was funded by Rhône Poulenc–Rorer, and in part by the British Heart Foundation. We are grateful to the Royal United Hospital, Bath, for providing saphenous vein samples and to the Gloucestershire Royal Hospital, especially Dr N. Shepherd for his histological analysis of tissue specimens.

Received October 16, 1997; accepted November 11, 1997.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27–33.[Medline] [Order article via Infotrieve]
2. Haraoka S, Shimokama T, Watanabe T. Participation of T lymphocytes in atherogenesis: sequential and quantitative observation of aortic lesions of rats with diet-induced hypercholesterolaemia using en face double immunostaining. Virchows Arch. 1995;426:307–315.[Medline] [Order article via Infotrieve]
3. Watanabe T, Shimokama T, Haraoka S, Kishikawa H. T lymphocytes in atherosclerotic lesions. Ann N Y Acad Sci. 1995;748:40–55.[Medline] [Order article via Infotrieve]
4. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57:791–804.[Medline] [Order article via Infotrieve]
5. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol. 1994;6:865–873.[Medline] [Order article via Infotrieve]
6. Furie MB, Randolph GJ. Chemokines and tissue injury. Am J Pathol. 1995;146:1287–1301.[Abstract]
7. Strieter RM, Koch AE, Antony VB, Fick RB, Standiford TJ, Kunkel SL. The immunopathology of chemotactic cytokines: the role of interleukin-8 and monocyte chemoattractant protein-1. J Lab Clin Med. 1994;123:183–197.[Medline] [Order article via Infotrieve]
8. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines—CXC and CC chemokines. Adv Immunol. 1994;55:97–179.[Medline] [Order article via Infotrieve]
9. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4⁺ and CD8⁺ T lymphocytes. FASEB J. 1994;8:1055–1060.[Abstract]
10. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunol Today. 1994;15:127–133.[Medline] [Order article via Infotrieve]
11. Kelner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, Copeland NG, Bazan JF, Moore KW, Schall TJ, Zlotnik A. Lymphotactin: a cytokine that represents a new class of chemokine. Science. 1994;266:1395–1399.[Abstract/Free Full Text]
12. Bazan JF, Bacon KB, Hardiman G, Wang W, Schall TJ. A new class of membrane bound chemokine with a CX₃C motif. Nature. 1997;385:640–644.[Medline] [Order article via Infotrieve]
13. Power CA, Wells TNC. Cloning and characterisation of human chemokine receptors. Trends Pharmacol Sci. 1996;17:209–213.[Medline] [Order article via Infotrieve]
14. Neote K, Di Gregorio D, Mak JY, Horuk R, Schall TJ. Molecular cloning, functional expression, and signalling characteristics of a C-C chemokine receptor. Cell. 1993;72:415–425.[Medline] [Order article via Infotrieve]
15. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci U S A. 1994;91:2752–2756.[Abstract/Free Full Text]
16. Combadiere C, Ahuja S, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem. 1995;270:16491–16494.[Medline] [Order article via Infotrieve]
17. Combadiere C, Ahuja SK, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem. 1995;270:30235. Erratum.[Abstract/Free Full Text]
18. Kitaura M, Nakajima T, Imai T, Harada S, Combadiere C, Tiffany HL, Murphy PM, Yoshie O. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem. 1996;271:7725–7730.[Abstract/Free Full Text]
19. Power CA, Meyer A, Nemeth K, Bacon KB, Hoogewerf AJ, Proudfoot AEI, Wells TNC. Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a human basophilic cell line. J Biol Chem. 1995;270:19495–19500.[Abstract/Free Full Text]
20. Gao J, Kuhns DB, Tiffany HL, McDermott D, Li X, Francke U, Murphy PM. Structure and functional expression of the human macrophage inflammatory protein 1/RANTES receptor. J Exp Med. 1993;177:1421–1427.[Abstract/Free Full Text]
21. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35:3362–3367.[Medline] [Order article via Infotrieve]
22. Baba M, Imai M, Nishimura M, Kakizaki S, Takagi S, Hieshima K, Nomiyama H, Yoshie O. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem. 1997;272:14893–14898.[Abstract/Free Full Text]
23. Yoshida R, Imai T, Hieshima J, Kusuda M, Baba M, Kitaura M, Nishimura M, Kakizaki M, Nomiyama H, Yoshie O. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem. 1997;272:13803–13809.[Abstract/Free Full Text]
24. Tiffany HL, Lautens LL, Gao J-L, Pease J, Locati M, Combadiere C, Modi W, Bonner TI, Murphy PM. Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309. J Exp Med. 1997;186:165–170.[Abstract/Free Full Text]
25. Holmes WE, Lee J, Kuang W, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science. 1991;253:1278–1280.[Abstract/Free Full Text]
26. Murphy PM, Tiffany HL. Cloning of complementary DNA encoding functional human interleukin-8 receptor. Science. 1991;253:1280–1283.[Abstract/Free Full Text]
27. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B. Chemokine receptor specific for IP-10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996;184:963–969.[Abstract/Free Full Text]
28. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, Springer TA. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382:829–832.[Medline] [Order article via Infotrieve]
29. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier J, Arenzana-Seisdedos F, Schwartz O, Heard J, Clark-Lewis I, Legler DF, Loetscher M, Baggiolini M, Moser B. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line–adapted HIV-1. Nature. 1996;382:833–835.[Medline] [Order article via Infotrieve]
30. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol. 1993;24:534–539.[Medline] [Order article via Infotrieve]
31. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121–1127.
32. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 1991;88:5252–5256.[Abstract/Free Full Text]
33. Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human monocyte chemoattractant protein-1 (MCP-1): full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene. FEBS Lett. 1989;244:487–493.[Medline] [Order article via Infotrieve]
34. Brown Z, Gerritsen ME, Carley WW, Strieter RM, Kunkel SL, Westwick J. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells: differential regulation of monocyte chemoattractant protein-1 and interleukin 8 in response to interferon-gamma. Am J Pathol. 1994;145:913–921.[Abstract]
35. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mantovani A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1166–1174.[Abstract/Free Full Text]
36. Jordan NJ, Watson ML, Williams RJ, Roach AG, Yoshimura T, Westwick J. Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol. 1997;122:749–757.[Medline] [Order article via Infotrieve]
37. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134–5138.[Abstract/Free Full Text]
38. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, Prusty S, Valente AJ, Schwartz CJ, Sonenshein GE. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci U S A. 1992;89:6953–6957.[Abstract/Free Full Text]
39. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039–2046.
40. Schall TJ. Biology of the RANTES/SIS cytokine family. Cytokine. 1991;3:165–183.[Medline] [Order article via Infotrieve]
41. Marfaing-Koka A, Devergne O, Gorgone G, Portier A, Schall TJ, Galanaud P, Emilie D. Regulation of the production of the RANTES chemokine by endothelial cells. J Immunol. 1995;154:1870–1878.[Abstract]
42. Yue T, Wang X, Sung C, Olson B, McKenna PJ, Gu J, Feuerstein GZ. Interleukin-8: a mitogen and chemoattractant for vascular smooth muscle cells. Circ Res. 1994;75:1–7.[Abstract/Free Full Text]
43. Ikeda U, Okada K, Ishikawa S, Saito T, Kasahara T, Shimada K. Monocyte chemoattractant protein 1 inhibits growth of rat vascular smooth muscle cells. Am J Physiol. 1995;268:H1021–H1026.[Abstract/Free Full Text]
44. Seino Y, Ikeda U, Takahashi M, Hojo Y, Irokawa M, Kasahara T, Shimada K. Expression of monocyte chemoattractant protein-1 in vascular tissue. Cytokine. 1995;7:575–579.[Medline] [Order article via Infotrieve]
45. Luo Y, D'Amore PA, Dorf ME. ß-Chemokine TCA3 binds to and activates rat vascular smooth muscle cells. J Immunol. 1996;157:2143–2148.[Abstract]
46. Hansel TT, De Vries IJM, Iff T, Rihs S, Wandzilak M, Betz S, Blaser K, Walker C. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods. 1991;145:105–110.[Medline] [Order article via Infotrieve]
47. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev. 1979;59:1–61.[Free Full Text]
48. Turner SJ, Ward SG, Smith G, Raport CJ, Schweikart V, Westwick J. Disparate signalling pathways utilised by HEK 293 cells transfected with MCP-1 type A or type B receptors. Br J Pharmacol. 1996;117:5. Abstract.[Medline] [Order article via Infotrieve]
49. Combadiere C, Ahuja SK, Van Damme J, Tiffany HL, Gao J, Murphy PM. Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine receptors 1 and 2B. J Biol Chem. 1995;270:29671–29675.[Abstract/Free Full Text]
50. Navab M, Hama SY, Nguyen TB, Fogelman AM. Monocyte adhesion and transmigration in atherosclerosis. Coron Artery Dis. 1994;5:198–204.[Medline] [Order article via Infotrieve]
51. Wilcox JN, Augustine AJ, Schall TJ, Gordon D. Local gene expression in human coronary arteries from transplanted hearts analyzed by in situ hybridization. Circulation. 1990;82:699. Abstract.
52. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley L, Colotta F, Mantovani A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine activated human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1165–1174.
53. Lukacs NW, Kunkel SL, Allen R, Evanoff HL, Shaklee CL, Sherman JS, Burdick MD, Strieter RM. Stimulus and cell-specific expression of C-X-C and C-C chemokines by pulmonary stromal cell populations. Am J Physiol. 1995;12:856–861.
54. Sica A, Matsushima K, Van Damme J, Wang JM, Polentarutti N, Dejana E, Colotta F, Mantovani A. IL-1 transcriptionally activates the neutrophil chemotactic factor/IL-8 gene in endothelial cells. Immunology. 1990;69:548–553.[Medline] [Order article via Infotrieve]
55. Grimm MC, Doe WF. Chemokines in inflammatory bowel disease mucosa: expression of RANTES, macrophage inflammatory protein MIP-1, MIP-1ß and gamma interferon–inducible protein-10 by macrophages, lymphocytes, endothelial cells and granulomas. Inflamm Bowel Dis. 1996;2:88–96.
56. Hoogewerf A, Black D, Proudfoot AEI, Wells TN, Power CA. Molecular cloning of murine CC CKR-4 and high affinity binding of chemokines to murine and human CC CKR-4. Biochem Biophys Res Commun. 1996;218:337–343.[Medline] [Order article via Infotrieve]
57. Turner L, Ward SG, Westwick J. RANTES-activated human T lymphocytes: a role for phosphoinositide 3-kinase. J Immunol. 1995;155:2437–2444.[Abstract]
58. Schonbeck U, Brandt E, Petersen F, Flad H, Loppnow H. IL-8 specifically binds to endothelial but not to smooth muscle cells. J Immunol. 1995;154:2375–2383.[Abstract]
59. Xu L, Rocnik E, Rahlpour R, Hunter N, Pickering G, Kelvin DJ. MCP-1 induces proliferation and migration of vascular smooth muscle cells. FASEB J. 1996;10:A1932. Abstract.
60. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, Nadal-Ginard B. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor–stimulated vascular smooth muscle cells. Circ Res. 1992;70:314–325.[Abstract/Free Full Text]
61. Graham GJ, Wright EG, Hewick R, Wolpe SD, Wilkie NM, Donaldson D, Lorimore S, Pragnell IB. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 1990;344:442–444.[Medline] [Order article via Infotrieve]
62. Parkinson EK, Graham GJ, Daubersies P, Burns JE, Heufler C, Plumb M, Schuler G, Pragnell IB. Hemopoietic stem cell inhibitor (SCI/MIP-1 alpha) also inhibits clonogenic epidermal keratinocyte proliferation. J Invest Dermatol. 1993;101:113–117.[Medline] [Order article via Infotrieve]
63. Hakovirta H, Vierula M, Wolpe SD, Parvinen M. MIP-1 is a regulator of mitotic and meiotic DNA synthesis during spermatogenesis. Mol Cell Endocrinol. 1994;99:119–124.[Medline] [Order article via Infotrieve]
64. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4⁺ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381:667–673.[Medline] [Order article via Infotrieve]
65. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381:661–666.[Medline] [Order article via Infotrieve]
66. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, Chan S, Roczniak S, Shaanafelt AB. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270:27348–27357.[Abstract/Free Full Text]